Allakos (NASDAQ:ALLK) slides 7.3% after Muddy Waters says it is short on the company, citing an undisclosed Phase 1 trial that “raises troubling concerns.”

From Muddy Waters’ tweet about the study: “Study uses 10 mg/kg (3x Phase 2 high dose). ALLK claims Phase 2 high dose reduced EOS 97%. Why test triple dose and risk adverse events if true?”

The tweet includes an attached Phase 1 consent form.





READ SOURCE

READ  HEXO EPS misses by C$0.18, misses on revenue

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here